Consolidated Statements of Cash Flows (Unaudited) - USD ($)	6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020
Cash flows from operating activities:
Net loss	$ (4,791,552)	$ (3,159,802)
Adjustments to reconcile net loss to net cash used by operating activities:
Depreciation and amortization expense	17,476	12,347
Stock-based compensation	59,094	41,119
Warrants	33,154	73,338
Discount for issue secured promissory note	500,000
Loss on debt modification	2,385,204
Change in fair value of derivative liability	(15,282)
Change in fair value of warrant liability	(438,972)
Leasing	(39,696)	74,470
Increase (decrease) in cash attributable to changes in operating assets and liabilities:
Accounts receivable	821
Prepaid expenses	11,563	(164,984)
Other assets		(40,000)
Accounts payable	267,823	506,229
Accrued expenses	(188,342)	8,118
Accounts payable and accrued expenses, related party	168,706	87,500
Accrued Interest	77,506	34,202
Accrued Interest, related party	572,346	481,088
Other liabilities	57,693	9,976
Net cash used by operating activities	(1,322,458)	(2,036,399)
Cash flows from investing activities:
Purchase of property and equipment	(31,617)	(18,676)
Cash received with merge with Boston Therapeutics	63,362
Net cash used by investing activities	31,745	(18,676)
Cash flows from financing activities:
Proceeds from notes payable	410,000	250,000
Proceeds from notes payable, related party	302,500	850,000
Proceeds from Secured Promissory Notes	4,500,000
Proceeds from borrowing PPP loan		402,154
Proceeds from issuance of common stock	23,450
Net cash provided by financing activities	5,235,950	1,502,154
Net increase (decrease) in cash	3,945,237	(552,921)
Cash at the beginning of the year	15,098	590,434
Cash at the end of the year	3,960,335	37,513
Non-cash investing and financing transactions:
Right-of-use asset obtained in exchange for lease obligations	(110,227)	(93,230)
Lease liability	149,923	18,760
Convertible notes payable for accrued expenses	50,000	75,000
Preferred stock conversion into common stock	$ 40,070,108